Evaluation of Two <i>EGFR</i> Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer

Evaluation of Two <i>EGFR</i> Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer

Epidermal growth factor receptor (<i>EGFR</i>) mutation testing is essential for individualized treatment using tyrosine kinase inhibitors. We evaluated two <i>EGFR</i> mutation tests, cobas v2 and PANAMutyper, for detection of <i>EGFR</i> activating mutations Ex1...

Full description

Bibliographic Details
Main Authors: Jeong-Oh Kim, Jung-Young Shin, Seo Ree Kim, Kab Soo Shin, Joori Kim, Min-Young Kim, Mi-Ran Lee, Yonggoo Kim, Myungshin Kim, Sook Hee Hong, Jin Hyoung Kang
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
circulating free dna
liquid biopsy
epidermal growth factor receptor
tyrosine kinase inhibitor
osimertinib
Online Access:https://www.mdpi.com/2072-6694/12/4/785

Internet

https://www.mdpi.com/2072-6694/12/4/785

Similar Items